Drug Profile


Alternative Names: AIDS-105293; Dapivirine gel; Dapivirine intravaginal ring; Dapivirine IVR; Dapivirine ring 004; R-147681; TMC-120

Latest Information Update: 21 Dec 2016

Price : $50

At a glance

  • Originator Tibotec BVBA
  • Developer International Partnership for Microbicides; Janssen Infectious Diseases BVBA
  • Class Antivirals; Nitriles; Pyrimidines; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV infections

Most Recent Events

  • 01 Dec 2016 The International Partnership for Microbicides completes a phase III trial for HIV infections (Prevention) in South Africa and Uganda (NCT01539226)
  • 05 Aug 2016 International Partnership for Microbicides plans a phase III trial in HIV infections (Prevention) in USA (NCT02862171)
  • 01 Aug 2016 International Partnership for Microbicides initiates the phase IIIb HOPE trial for HIV infections (Prevention) in South Africa (Vaginal, Ring) (NCT02858037)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top